NCT06958224Recruiting
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers, Not Eligible for Initial Sequencing in Clinical Routine and Selected From the First Line in Molecular Tumour Board.
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical research in cancers. * Accordingly, this project aims to study the contribution of early systematic multigene sequencing (NGS) discussed in Molecular Tumour Board for poor prognosis cancers, with no current indication for early sequencing. * The investigators teams propose to perform a randomized study in tumours in which actionable therapeutic targets according to the ESMO ESCAT scale are known (ESCAT II/IV) especially in pancreatic ductal adenocarcinoma, hepatocellular carcinoma or triple negative breast cancer. Two approaches will be compared: a large multigenic early sequencing approach since the first line setting versus a Plan France Medecine Genomique 2025 approach since the second line setting. The frequency of really initiated therapeutic proposals according to the molecular status will be compared in each group.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- First submitted
- 16 Apr 2025
- Start date
- 29 Apr 2026
- Primary completion date
- 10 Nov 2028
- Lead sponsor
- University Hospital, Lille
- NCT number
- NCT06958224
What you commit to
- Study type: Interventional
- Planned participants: 360
- From 29 Apr 2026 to the primary completion date, 10 Nov 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- General condition WHO \>1 and/or nutritional status not compatible with a therapeutic proposal
- Active infection or active chronic disease (diabetes, liver dysfunction, immune disease) making the patient's condition incompatible with a therapeutic proposal.
Other
- Limiting systemic cardiovascular, renal, bronchopulmonary or endocrinological comorbidities with the initiation of a therapeutic proposal
- A priori unavailable, in insufficient quantity or of suboptimal quality tumour material.
- Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign consent.
Who the study is looking for
- \- Age \>18 years.
- Advanced disease status ("unresectable" or "metastatic").
- Patient included either at the time of diagnostic investigation or during first line of treatment.
- Good general conditions, still compatible with a therapeutic proposal, WHO 0-1.
- The following tumour sites, with poor prognosis and for which ESCAT II/IV treatment targets can be found according to ESMO:
- pancreatic adenocarcinoma
- hepatocellular carcinomas,
- triple negative breast cancer.
- Tumour tissue a priori available in sufficient quantity: at least one biopsy from a visceral metastatic site or surgical specimen (if available) for eligible cancers.
- Patient covered by a social sercurity scheme
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Claude Huriez - Service Oncologie Coordinator of this site? Confirm its status | Lille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.